AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7549079 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer antithrombotic and antiplatelet agents (hirudin, glycoprotein IIb/IIIa receptor antagonists)
Number of subjects: 0
Study 1853532 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Number of subjects: 0
Study 6975823 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim (300 mg once a day for seven days)
Number of subjects: 0
Study 6975823 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole (160 mg trimethoprim, 800 mg sulphamethoxazole, two tablets twice a day for seven days)
Number of subjects: 0
Study 6975823 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim and co-trimoxazole
Number of subjects: 0
Study 6975823 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 0
Study 31766743 — intervention group
Group type: EXPERIMENTAL
Intervention: l-Carnitine administration (200 mg/kg/day)
Number of subjects: 0
Study 31766743 — intervention group
Group type: EXPERIMENTAL
Intervention: l-Carnitine administration (50-100 mg/kg/day)
Number of subjects: 0
Study 31766743 — intervention group
Group type: EXPERIMENTAL
Intervention: l-Carnitine administration
Number of subjects: 0
Study 31766743 — intervention group
Group type: EXPERIMENTAL
Intervention: l-Carnitine administration in ASD associated with genetic disorders
Number of subjects: 0
Study 27956393 — intervention group
Group type: EXPERIMENTAL
Intervention: Video plus sucrose plus liposomal lidocaine
Number of subjects: 352
Study 27956393 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 352
Study 27956393 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-directed video education about infant soothing
Number of subjects: 352
Study 27956393 — intervention group
Group type: EXPERIMENTAL
Intervention: Video plus sucrose
Number of subjects: 352
Study 25849853 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic and aerobic exercises
Number of subjects: 42
Study 25849853 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 23513249 — intervention group
Group type: COMPARATOR
Intervention: Continuous oxygen flow by standard nasal cannula (CFNC)
Number of subjects: 59
Study 23513249 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse demand oxygen delivery (DOD)
Number of subjects: 59
Study 23513249 — intervention group
Group type: EXPERIMENTAL
Intervention: Pendant reservoir cannula (PRC)
Number of subjects: 59
Study 21546089 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg VEGF Trap‐Eye every 4 weeks
Number of subjects: 221
Study 21546089 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg VEGF Trap‐Eye every 4 weeks
Number of subjects: 221
Study 21546089 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg VEGF Trap‐Eye for 3 initial monthly doses and then every 8 weeks
Number of subjects: 221
Study 21546089 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg VEGF Trap‐Eye for 3 initial monthly doses and then on an as‐needed (PRN) basis
Number of subjects: 221
Study 21546089 — intervention group
Group type: COMPARATOR
Intervention: macular laser photocoagulation
Number of subjects: 221
Study 19706572 — intervention group
Group type: COMPARATOR
Intervention: Hospital crib
Number of subjects: 200
Study 19706572 — intervention group
Group type: EXPERIMENTAL
Intervention: Car bed
Number of subjects: 200
Study 19706572 — intervention group
Group type: EXPERIMENTAL
Intervention: Car seat
Number of subjects: 200
Study 17278206 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation and anti-H pylori therapy
Number of subjects: 22
Study 17278206 — intervention group
Group type: COMPARATOR
Intervention: Iron supplementation only
Number of subjects: 22
Study 15083479 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian, counterfactual approach using data augmentation (DA) algorithm
Number of subjects: 0
Study 15083479 — intervention group
Group type: COMPARATOR
Intervention: Likelihood-based, counterfactual approach based on the EM algorithm
Number of subjects: 0
Study 11597814 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (HFRT) - 59.4 Gy in 54 1.1-Gy twice daily fractions
Number of subjects: 490
Study 11597814 — intervention group
Group type: COMPARATOR
Intervention: Conventionally fractionated radiotherapy (CFRT) - 50.4 Gy in 28 1.8-Gy daily fractions
Number of subjects: 490
Study 11597814 — intervention group
Group type: EXPERIMENTAL
Intervention: HFRT
Number of subjects: 490
Study 11597814 — intervention group
Group type: COMPARATOR
Intervention: CFRT
Number of subjects: 490
Study 9588436 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of donepezil hydrochloride
Number of subjects: 468
Study 9588436 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of donepezil hydrochloride
Number of subjects: 468
Study 9588436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study 7985937 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (standard therapy regimen)
Number of subjects: 18
Study 7985937 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B (standard therapy regimen plus plasmapheresis)
Number of subjects: 18
Study 7985937 — intervention group
Group type: COMPARATOR
Intervention: Protocol C (standard therapy regimen plus pulse methylprednisolone)
Number of subjects: 18
Study 2574553 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine 60 mg every 12 hours
Number of subjects: 26
Study 2574553 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine 120 mg each day
Number of subjects: 26
Study 2574553 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 26
Study 1102656 — intervention group
Group type: EXPERIMENTAL
Intervention: alexidine mouthwash
Number of subjects: 45
Study 1102656 — intervention group
Group type: COMPARATOR
Intervention: placebo mouthwash
Number of subjects: 45
Study 31794542 — intervention group
Group type: EXPERIMENTAL
Intervention: Microblepharon exfoliation
Number of subjects: 30
Study 31312144 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Contraceptives (30 μg ethinyl estradiol)
Number of subjects: 28
Study 31312144 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Contraceptives (20 μg ethinyl estradiol)
Number of subjects: 28
Study 31312144 — intervention group
Group type: COMPARATOR
Intervention: NOC (non-OC users)
Number of subjects: 28
Study 31312144 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OC and NOC groups
Number of subjects: 28
Study 28291675 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral protection device (CPD) usage by vascular surgeons
Number of subjects: 831
Study 28291675 — intervention group
Group type: COMPARATOR
Intervention: Choice of stent and CPD based on plaque characteristics
Number of subjects: 831
Study 24171791 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% sodium‐Hyaluronate
Number of subjects: 38
Study 24171791 — intervention group
Group type: COMPARATOR
Intervention: Intraocular irrigating solution
Number of subjects: 38
Study 23302232 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI) using the transarterial CoreValve System (Medtronic Inc.)
Number of subjects: 280
Study 23302232 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 280
Study 23302232 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI
Number of subjects: 280
Study 21227945 — intervention group
Group type: EXPERIMENTAL
Intervention: ExAmen (n = 24)
Number of subjects: 50
Study 21227945 — intervention group
Group type: COMPARATOR
Intervention: ExOvul (n = 26)
Number of subjects: 50
Study 21227945 — intervention group
Group type: EXPERIMENTAL
Intervention: ExAmen
Number of subjects: 50
Study 21227945 — intervention group
Group type: COMPARATOR
Intervention: ExOvul
Number of subjects: 50
Study 16443353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide (80 or 160 microg daily)
Number of subjects: 0
Study 16443353 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone (100 microg twice daily)
Number of subjects: 0
Study 16443353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide (160 microg daily)
Number of subjects: 0
Study 16443353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide and Fluticasone (both groups)
Number of subjects: 0
Study 12960650 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (1.5 mg/kg)
Number of subjects: 27
Study 12960650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 10780503 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire of Smoking Urges (QSU)
Number of subjects: 0
Study 10780503 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary reinforcement (puffs on a cigarette)
Number of subjects: 0
Study 10780503 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary reinforcement (tokens for puffs on a cigarette)
Number of subjects: 0
Study 10780503 — intervention group
Group type: EXPERIMENTAL
Intervention: PR performance under primary reinforcement
Number of subjects: 0
Study 10780503 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlations between PR and QSU measures
Number of subjects: 0
Study 8739820 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 55
Study 1831005 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermal pretreatment with 0.5% hydrocortisone cream
Number of subjects: 10
Study 1831005 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermal pretreatment with magnesium-aluminum hydroxide suspension
Number of subjects: 10
Study 1831005 — intervention group
Group type: COMPARATOR
Intervention: Transdermal patch alone
Number of subjects: 10
Study 1831005 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (hydrocortisone, magnesium-aluminum hydroxide, patch alone)
Number of subjects: 10
Study 7049351 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid, 3 g/day
Number of subjects: 49
Study 7049351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 31481688 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS to left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 19
Study 31481688 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 19
Study 28499979 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 26
Study 28499979 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 28499979 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study 26541921 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivessel revascularization
Number of subjects: 664
Study 26541921 — intervention group
Group type: COMPARATOR
Intervention: No multivessel revascularization
Number of subjects: 664
Study 24216182 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (MSCs) alone
Number of subjects: 22
Study 24216182 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (MSCs) combined with cord blood (CB)
Number of subjects: 22
Study 24216182 — intervention group
Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 22
Study 24216182 — intervention group
Group type: COMPARATOR
Intervention: Disease-free survival
Number of subjects: 22
Study 24216182 — intervention group
Group type: COMPARATOR
Intervention: Cumulative incidence of tumor relapse
Number of subjects: 22
Study 22113980 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation template implantation (NT group, n=11)
Number of subjects: 22
Study 22113980 — intervention group
Group type: COMPARATOR
Intervention: Conventional THA (control group, n=11)
Number of subjects: 22
Study 19378912 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supine cycle exercise (Exercise group; N = 14)
Number of subjects: 21
Study 19378912 — intervention group
Group type: COMPARATOR
Intervention: No exercise (Rest group; N = 7)
Number of subjects: 21
Study 19378912 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Exercise and Rest)
Number of subjects: 21
Study 17387462 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran co-administered with azithromycin
Number of subjects: 80
Study 17387462 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran co-administered with cefuroxime
Number of subjects: 80
Study 17387462 — intervention group
Group type: COMPARATOR
Intervention: Ximelagatran co-administered with amoxicillin, doxycycline, or ciprofloxacin
Number of subjects: 80
Study 15467565 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned cesarean section
Number of subjects: 917
Study 15467565 — intervention group
Group type: COMPARATOR
Intervention: Planned vaginal birth
Number of subjects: 917
Study 11441386 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm Ability Training (AAT) with knowledge of results
Number of subjects: 60
Study 11441386 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm Ability Training (AAT) without knowledge of results
Number of subjects: 60
Study 11441386 — intervention group
Group type: COMPARATOR
Intervention: No Arm Ability Training (Control)
Number of subjects: 60
Study 11441386 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm Ability Training (AAT)
Number of subjects: 60
Study 11103296 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea without milk
Number of subjects: 9
Study 11103296 — intervention group
Group type: COMPARATOR
Intervention: Black tea with milk
Number of subjects: 9
Study 11103296 — intervention group
Group type: COMPARATOR
Intervention: No tea
Number of subjects: 9
Study 9049513 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine coat-core (nisoldipine-CC)
Number of subjects: 542
Study 8396103 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin, single daily dose of 10 mg/kg (maximum 500 mg) for three days (n = 46)
Number of subjects: 93
Study 8396103 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin ethylsuccinate, 30‐50 mg/kg daily in three divided doses for ten days (n = 47)
Number of subjects: 93
Study 8396103 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 93
Study 8396103 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 93
Study 2424759 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg b.i.d.
Number of subjects: 301
Study 2424759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 2424759 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 301
Study 30383633 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management intervention over 10 weeks
Number of subjects: 28
Study 30383633 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 28
Study 27181507 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY‐CRM
Number of subjects: 202
Study 27181507 — intervention group
Group type: COMPARATOR
Intervention: MenACWY‐TT
Number of subjects: 202
Study 24170106 — intervention group
Group type: EXPERIMENTAL
Intervention: LB03002 (once-weekly)
Number of subjects: 178
Study 24170106 — intervention group
Group type: COMPARATOR
Intervention: Daily GH (daily)
Number of subjects: 178
Study 24170106 — intervention group
Group type: EXPERIMENTAL
Intervention: LB03002 (once-weekly throughout)
Number of subjects: 178
Study 24170106 — intervention group
Group type: EXPERIMENTAL
Intervention: LB03002 (switched to)
Number of subjects: 178
Study 24170106 — intervention group
Group type: EXPERIMENTAL
Intervention: LB03002
Number of subjects: 178
Study 22874850 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-synthetic DTwP vaccine
Number of subjects: 331
Study 22874850 — intervention group
Group type: COMPARATOR
Intervention: Routine DTwP vaccine
Number of subjects: 331
Study 20517329 — intervention group
Group type: EXPERIMENTAL
Intervention: Q‐500 (500 mg/day)
Number of subjects: 1002
Study 20517329 — intervention group
Group type: EXPERIMENTAL
Intervention: Q‐1000 (1000 mg/day)
Number of subjects: 1002
Study 20517329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1002
Study 18281659 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and etoposide with oblimersen (arm A)
Number of subjects: 56
Study 18281659 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and etoposide without oblimersen (arm B)
Number of subjects: 56
Study 15885050 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolperisone (300-900 mg daily)
Number of subjects: 120
Study 15885050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 15885050 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolperisone
Number of subjects: 120
Study 12646342 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 580
Study 10474578 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma clinics (three sessions over six months involving nurse counselling, education about asthma management, spirometry, and consultation with the general practitioner)
Number of subjects: 195
Study 10474578 — intervention group
Group type: COMPARATOR
Intervention: Standard general practice care
Number of subjects: 195
Study 8707025 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 10 mg o.d.
Number of subjects: 14
Study 8707025 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine AR 20 mg b.d.
Number of subjects: 14
Study 8707025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1679569 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (azathioprine + sulfasalazine)
Number of subjects: 140
Study 1679569 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 140
Study 1679569 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine
Number of subjects: 140
Study 30127297 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentrate omega-3 (MF4637) for 24 weeks
Number of subjects: 176
Study 30127297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 26784000 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 122
Study 26784000 — intervention group
Group type: COMPARATOR
Intervention: Physicians' choice
Number of subjects: 122
Study 26784000 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended ofatumumab treatment
Number of subjects: 122
Study 24798419 — intervention group
Group type: EXPERIMENTAL
Intervention: Training course for general practice nurses (16-hour Self-determination theory-based course over 10 months)
Number of subjects: 4034
Study 22558609 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA) 300 mg in the morning and 600 mg in the evening for 7 days, then 300 mg twice a day for 7 more days
Number of subjects: 24
Study 22558609 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 600 mg three times a day for 2 weeks
Number of subjects: 24
Study 20438630 — intervention group
Group type: EXPERIMENTAL
Intervention: Humalog Mix 25
Number of subjects: 11
Study 20438630 — intervention group
Group type: COMPARATOR
Intervention: Humalog Mix 50
Number of subjects: 11
Study 19040016 — intervention group
Group type: EXPERIMENTAL
Intervention: Early submaximal cardiopulmonary exercise test (CPET) and cardiac rehabilitation for 3 months
Number of subjects: 94
Study 19040016 — intervention group
Group type: COMPARATOR
Intervention: Control group conducting exercise according to their needs
Number of subjects: 94
Study 16741684 — intervention group
Group type: EXPERIMENTAL
Intervention: Penn Resiliency Program (PRP)
Number of subjects: 271
Study 16741684 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 271
Study 12679767 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban infusion
Number of subjects: 96
Study 12679767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 11029126 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg kg(‐1) cisatracurium
Number of subjects: 30
Study 11029126 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg kg(‐1) cisatracurium
Number of subjects: 30
Study 8717544 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual energy X-ray absorptiometry (DXA)
Number of subjects: 0
Study 8717544 — intervention group
Group type: EXPERIMENTAL
Intervention: DXA with relevant site-specific parameters
Number of subjects: 0
Study 8717544 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality operator performance
Number of subjects: 0
Study 8717544 — intervention group
Group type: EXPERIMENTAL
Intervention: DXA measurement
Number of subjects: 0
Study 8717544 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed analytic methods
Number of subjects: 0
Study 1305331 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms sublingual GTN
Number of subjects: 7
Study 1305331 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg buccal GTN
Number of subjects: 7
Study 1305331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 4066577 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity group (A)
Number of subjects: 89
Study 4066577 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 89
Study 31145432 — intervention group
Group type: EXPERIMENTAL
Intervention: Static treatment protocol
Number of subjects: 0
Study 31145432 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic treatment protocol
Number of subjects: 0
Study 29447199 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV-16
Number of subjects: 40
Study 29447199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30592818 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 76
Study 30592818 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 76
Study 30592818 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Sevoflurane and Desflurane)
Number of subjects: 76
Study 24785750 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors (PRGF)
Number of subjects: 20
Study 24785750 — intervention group
Group type: COMPARATOR
Intervention: Control (natural healing)
Number of subjects: 20
Study 22334369 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30-45 mg/day plus standard care (peginterferon alpha-2a plus ribavirin for 48 weeks)
Number of subjects: 150
Study 22334369 — intervention group
Group type: COMPARATOR
Intervention: Standard care (peginterferon alpha-2a plus ribavirin for 48 weeks)
Number of subjects: 150